By Business/Source
Currency:USD
2025/FY
Stock NameRevenueRatio
Research and development of a broad pipeline of novel immunotherapies10M100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
United States10M100.00%